KEVIN ERICKSON to Cost-Benefit Analysis
This is a "connection" page, showing publications KEVIN ERICKSON has written about Cost-Benefit Analysis.
Connection Strength
0.395
-
The cost-effectiveness of lipid lowering for primary cardiovascular prevention in chronic kidney disease: moving beyond statins. Kidney Int. 2019 07; 96(1):22-25.
Score: 0.138
-
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med. 2013 Sep 17; 159(6):382-9.
Score: 0.092
-
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol. 2013 Mar 26; 61(12):1250-8.
Score: 0.089
-
The challenges of cost-effectiveness analyses for the clinician. Am J Kidney Dis. 2010 Dec; 56(6):1023-5.
Score: 0.076